29 completed, 5 terminated, 3 unknown, 1 active not recruiting. 39 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 39 | Completed 29, Terminated 5, Unknown 3, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Uterine Cervical Dysplasia: new trials by email Literature Review of Uterine Cervical Dysplasia trials Research Report on Uterine Cervical Dysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 Gardasil-9, Placebo - Cervical Intraepithelial Neoplasia | Phase 3 | Not yet recruiting | Alessandro Ghelardi | 1220 | 2020-12-01 | 2020-11-05 |
| DNA Methylation Testing for the Screening of Uterine Cervical Lesion Host DNA methylation testing, Cervical cytology and/or high-risk human papillomavirus assays - Cervical Cancer, Cervical Intraepithelial Neoplasia | Phase 3 | Unknown | Lei Li | 12000 | 2020-11-26 | 2020-11-30 |
| Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Nonavalent HPV vaccine, Bivalent HPV vaccine - Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 3 | Active not recruiting | Xiamen University | 9327 | 2020-09-05 | 2025-11-21 |
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Matched Placebo, CELLECTRA™-5PSP - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 203 | 2019-02-28 | 2024-10-17 |
| A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) V501 - Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ | Phase 3 | Completed | Merck Sharp & Dohme LLC | 766 | 2018-08-31 | 2024-12-31 |
| A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study Blood sampling for antibody determination - Cervical Intraepithelial Neoplasia | Phase 3 | Completed | GlaxoSmithKline | 228 | 2018-02-28 | 2020-11-19 |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) VGX-3100, Placebo, Electroporation (EP) - Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion | Phase 3 | Completed | Inovio Pharmaceuticals | 201 | 2017-06-28 | 2023-07-27 |
| Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol Imiquimod, LLETZ - Cervical Intraepithelial Neoplasia | Phase 3 | Unknown | Erasmus Medical Center | 433 | 2016-05-01 | 2018-02-06 |
| A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine - Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 3 | Completed | Jun Zhang | 979 | 2015-12-05 | 2018-08-16 |
| Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Imiquimod, Loop Electrosurgical Excision Procedure - Cervical Intraepithelial Neoplasia | Phase 2 / Phase 3 | Completed | United States Naval Medical Center, San Diego | 22 | 2015-02-01 | 2017-06-27 |
| Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix AV2, Placebo - Uterine Cervical Dysplasia, Papillomavirus Infections | Phase 3 | Completed | Jean-Pierre Van geertruyden | 327 | 2015-01-01 | 2018-10-12 |
| Imiquimod Treatment of CIN Lesions Imiquimod, LLETZ - Cervical Intraepithelial Neoplasia | Phase 3 | Terminated | Maastricht University Medical Center | 9 | 2014-12-01 | 2018-08-15 |
| A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. HPV-16/18 vaccine, HPV-16/18 placebo - Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 3 | Completed | Shanghai Zerun Biotechnology Co.,Ltd | 12000 | 2014-11-02 | 2022-12-19 |
| Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial Spray, Forced - Uterine Cervical Dysplasia | Phase 3 | Completed | Ruhr University of Bochum | 160 | 2014-01-01 | 2022-07-08 |
| Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia Topical Imiquimod, Conization - Cervical Intraepithelial Neoplasia | Phase 3 | Terminated | Medical University of Vienna | 95 | 2013-05-01 | 2016-11-01 |
| Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine HPV Vaccine, HEV vaccine - Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 3 | Completed | Xiamen University | 7372 | 2012-11-22 | 2020-02-24 |
| Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial Lidocaine spray, Lidocaine submucosal injection - Uterine Cervical Dysplasia | Phase 3 | Completed | Chiang Mai University | 101 | 2011-09-01 | 2013-01-15 |
| Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) offer of vaginal self collection, 2nd reminder letter for Pap testing - Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia | Phase 2 / Phase 3 | Unknown | McMaster University | 1440 | 2010-04-01 | 2011-07-21 |
| Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Screening test - Uterine Cervical Neoplasms, Uterine Cervical Dysplasia | Phase 3 | Completed | University Hospital, Tours | 734 | 2009-09-01 | 2011-05-13 |
| ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Topical imiquimod therapy - Cervical Intraepithelial Neoplasia | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 60 | 2009-07-01 | 2011-01-24 |
Showing 20 of 39. Sign in to see all of them.
Uterine Cervical Neoplasms (14) · Papillomavirus Infections (5) · Precancerous Conditions (3) · AIDS-Related Complex (2) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Hyperthermia (2) · Persistent Infection (2) · Squamous Intraepithelial Lesions (2) · Uterine Cervical Diseases (2) · Atypical Squamous Cells of the Cervix (1) · Condylomata Acuminata (1) · Infections (1) · Lymphedema (1)
Female Urogenital Diseases (39) · Female Urogenital Diseases and Pregnancy Complications (39) · Genital Diseases (39) · Genital Diseases, Female (39) · Urogenital Diseases (39) · Uterine Diseases (39) · Neoplasms (38) · Uterine Cervical Diseases (37) · Precancerous Conditions (36) · Genital Neoplasms, Female (14) · Neoplasms by Site (14) · Urogenital Neoplasms (14) · Uterine Neoplasms (14) · Pathological Conditions, Signs and Symptoms (12) · Infections (9)
Imiquimod (5) · human papillomavirus vaccine, L1 type 16, 18 (4) · Blood Specimen Collection (2) · Colposcopy (2) · Conization (2) · VGX-3100 (2) · Vaginal Smears (2) · AKAP13 protein, human (1) · Cryosurgery (1) · Electroporation (1) · Fenretinide (1) · Fluorouracil (1) · Hepatitis A Vaccines (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Isotretinoin (1)
GlaxoSmithKline (5) · Inovio Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · Medical University of Vienna (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Oswaldo Cruz Foundation (2) · Xiamen University (2) · Alessandro Ghelardi (1) · Barts and the London School of Medicine and Dentistry (1) · Chiang Mai University (1) · Columbia University (1) · Eisai Inc. (1) · Erasmus Medical Center (1) · Gen-Probe, Incorporated (1) · Gynecologic Oncology Group (1)
United States (13) · China (6) · Brazil (4) · Puerto Rico (4) · Canada (3) · Estonia (3) · Germany (3) · South Africa (3) · Argentina (2) · Austria (2) · Finland (2) · Lithuania (2) · Netherlands (2) · Poland (2) · Spain (2)
Jeffrey Skolnik, MD (2) · Addie N Alkhas, MD (1) · Alan Arslan, M.D. (1) · Alberto Manetta, MD (1) · Alessandro Ghelardi, MD (1) · Alex Mutombo Baleka, MD (1) · Alice Lytwyn, MD, FRCPC (1) · Arnold J Kruse, MD, PhD (1) · Asama Vanichtantikul, M.D. (1) · Clemens B Tempfer, MD (1) · Giuseppe Del Priore, M.D., M.P.H. (1) · Helen E. Rhodes, MD (1) · Hong-xing Pan, master (1)
PMID 22914404, PMID 10451482, PMID 10764464, PMID 10796771, PMID 16264158, PMID 16264159, PMID 1731281, PMID 17699008, PMID 17919718, PMID 17959735, PMID 18948732, PMID 19586656, PMID 19939441, PMID 19943823, PMID 20197322, PMID 20706107, PMID 20952254, PMID 21173650, PMID 21345402, PMID 21865087, PMID 22177579, PMID 22265115, PMID 22771223, PMID 22850119, PMID 23094124, PMID 23117059, PMID 23489374, PMID 23834901, PMID 23843155, PMID 23873171, PMID 23921860, PMID 24014882, PMID 24201682, PMID 24436334, PMID 24958910, PMID 25018097, PMID 25139208, PMID 25220842, PMID 25424783, PMID 25516462, PMID 25783647, PMID 25796338, PMID 26071347, PMID 26346155, PMID 26467666, PMID 26796660, PMID 26892991, PMID 26897518, PMID 28173776, PMID 29696202
2018 (2), 2015 (1), 2016 (1), 2017 (1), 2023 (1), P30CA016672 (1), U10CA101165 (1)